Skip to main content
. 2024 Jun 28;14(8):1365–1377. doi: 10.1002/2211-5463.13499

Fig. 4.

Fig. 4

Liraglutide enhanced the antitumor efficacy of PD‐1 blockade. Tumor volumes were monitored in (A) LLC or (B) Hepa1‐6 allograft mice treated by IgG isotype control (isotype), anti‐PD‐1 mAb (αPD‐1), liraglutide, or liraglutide and anti‐PD‐1 mAb (liraglutide+αPD‐1). (C) LLC and (D) Hepa1‐6 tumor volumes for the NETs‐removed C57BL/6 mice. NETs were removed using DNase I (5 mg·kg−1). (E) LLC and (F) Hepa1‐6 tumor volumes for the NETs‐removed C57BL/6 mice accepting isotype, αPD‐1, liraglutide, or liraglutide+αPD‐1 treatments. NETs were removed using DNase I (5 mg·kg−1). Tumor volume = 0.5 × length × width2. Statistical significance was determined with two‐way ANOVA tests. N = 12 mice for every group. Nonparametric tests were utilized to assess statistical significance between different treatment groups. **P < 0.01, ***P < 0.001. Error bars represent SD.